eloralintide vs retatrutide Retatrutide, Eli Lilly's next obesity shot, showed far more weight loss in clinical trial patients than other blockbuster obesity drugs. MORE BELOW ⬇️ Weight loss with retatrutide as

The normal daily hair loss seems to decrease

Enhanced Endurance and Athletic Performance Boosts stamina and recovery

Key Takeaways Retatrutide targets three hormones (GLP-1, GIP, glucagon), tirzepatide targets two (GLP-1, GIP), and semaglutide targets one (GLP-1) At 68 weeks, retatrutide achieved 28.7% average weight loss, tirzepatide approximately 22%, and semaglutide around 17% on the highest doses Side effects are similar across all three medications, mainly digestive issues like nausea and diarrhoea Retatrutide is not yet approved and won't be available until mid-2026 at the earliest Retatrutide is not yet approved and is not currently available in the UK Tirzepatide (Mounjaro) and semaglutide (Wegovy) are both available now in the UK through NHS or private providers By entering I agree to the Terms and Conditions

doi:10.1126/science.1175371